Apellis Announces Craig Wheeler to Join the Board of Directors
Apellis Pharmaceuticals (APLS) has announced the immediate appointment of Craig Wheeler to its Board of Directors. Wheeler, currently founder and CEO of Headwaters Biotech Advisors, brings over 30 years of biopharmaceutical leadership experience.
Wheeler's notable experience includes a 14-year tenure as president and CEO of Momenta Pharmaceuticals, leading the company through multiple product launches until its acquisition by Johnson and Johnson in 2020. He also served as president of Chiron Biopharmaceuticals, managing a global unit of 2,500 employees.
Currently serving on the Board of Directors of Amicus Therapeutics, Wheeler holds an MBA from the Wharton School and both BS and MS degrees in Chemical Engineering from Cornell University.
Apellis Pharmaceuticals (APLS) ha annunciato la nomina immediata di Craig Wheeler nel suo Consiglio di Amministrazione. Wheeler, attualmente fondatore e CEO di Headwaters Biotech Advisors, vanta oltre 30 anni di esperienza nel settore biofarmaceutico.
Tra le sue esperienze più rilevanti, vi è un mandato di 14 anni come presidente e CEO di Momenta Pharmaceuticals, durante il quale ha guidato l’azienda attraverso il lancio di diversi prodotti fino all’acquisizione da parte di Johnson and Johnson nel 2020. Ha inoltre ricoperto il ruolo di presidente di Chiron Biopharmaceuticals, gestendo un’unità globale composta da 2.500 dipendenti.
Attualmente membro del Consiglio di Amministrazione di Amicus Therapeutics, Wheeler è in possesso di un MBA presso la Wharton School e di lauree BS e MS in Ingegneria Chimica presso la Cornell University.
Apellis Pharmaceuticals (APLS) ha anunciado el nombramiento inmediato de Craig Wheeler en su Junta Directiva. Wheeler, fundador y CEO de Headwaters Biotech Advisors, aporta más de 30 años de experiencia en liderazgo biofarmacéutico.
Su experiencia destacada incluye un periodo de 14 años como presidente y CEO de Momenta Pharmaceuticals, liderando la empresa durante varios lanzamientos de productos hasta su adquisición por Johnson and Johnson en 2020. También fue presidente de Chiron Biopharmaceuticals, gestionando una unidad global de 2,500 empleados.
Actualmente forma parte de la Junta Directiva de Amicus Therapeutics y posee un MBA de la Wharton School, además de títulos BS y MS en Ingeniería Química de la Universidad de Cornell.
Apellis Pharmaceuticals (APLS)가 크레이그 휠러를 이사회에 즉시 임명했다고 발표했습니다. 현재 Headwaters Biotech Advisors의 창립자 겸 CEO인 휠러는 30년 이상의 바이오제약 분야 리더십 경험을 보유하고 있습니다.
휠러의 주요 경력으로는 모멘타 파마슈티컬스에서 14년간 사장 겸 CEO로 재직하며 다수의 제품 출시를 이끌었고, 2020년 존슨앤드존슨에 인수될 때까지 회사를 이끌었습니다. 또한 Chiron Biopharmaceuticals의 사장으로서 2,500명의 글로벌 직원을 관리했습니다.
현재 Amicus Therapeutics 이사회 멤버로 활동 중이며, 휠러는 와튼 스쿨에서 MBA를, 코넬 대학교에서 화학공학 학사 및 석사 학위를 취득했습니다.
Apellis Pharmaceuticals (APLS) a annoncé la nomination immédiate de Craig Wheeler à son conseil d’administration. Wheeler, actuellement fondateur et PDG de Headwaters Biotech Advisors, possède plus de 30 ans d’expérience dans le secteur biopharmaceutique.
Parmi ses expériences notables, il a occupé pendant 14 ans le poste de président-directeur général de Momenta Pharmaceuticals, dirigeant l’entreprise à travers plusieurs lancements de produits jusqu’à son acquisition par Johnson and Johnson en 2020. Il a également été président de Chiron Biopharmaceuticals, supervisant une unité mondiale de 2 500 employés.
Il siège actuellement au conseil d’administration d’Amicus Therapeutics et détient un MBA de la Wharton School ainsi que des diplômes BS et MS en génie chimique de l’Université Cornell.
Apellis Pharmaceuticals (APLS) hat die sofortige Ernennung von Craig Wheeler in den Vorstand bekannt gegeben. Wheeler, derzeit Gründer und CEO von Headwaters Biotech Advisors, bringt über 30 Jahre Führungserfahrung in der Biopharma-Branche mit.
Zu seinen bemerkenswerten Erfahrungen zählt eine 14-jährige Tätigkeit als Präsident und CEO von Momenta Pharmaceuticals, wo er das Unternehmen durch mehrere Produkteinführungen bis zur Übernahme durch Johnson and Johnson im Jahr 2020 leitete. Zudem war er Präsident von Chiron Biopharmaceuticals und verantwortete eine globale Einheit mit 2.500 Mitarbeitern.
Derzeit ist Wheeler Mitglied im Vorstand von Amicus Therapeutics und verfügt über einen MBA der Wharton School sowie einen BS- und MS-Abschluss in Chemieingenieurwesen von der Cornell University.
- Addition of seasoned executive with extensive commercial leadership experience
- Wheeler's successful track record in growing biopharmaceutical companies and product launches
- Experience in immunology sector relevant to Apellis's portfolio
- None.
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry.
“We are thrilled to welcome Craig to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines. His expertise will be a tremendous asset to our Board as we continue to deliver innovative therapies to patients.”
Mr. Wheeler previously served as president and chief executive officer of Momenta Pharmaceuticals. During his 14-year tenure, he led the company from its early stages through multiple product launches and ultimately its acquisition by Johnson and Johnson in 2020. Prior to Momenta, he was president of Chiron Biopharmaceuticals, where he led a fully integrated global pharmaceutical business unit of approximately 2,500 global employees. He currently serves on the Board of Directors of Amicus Therapeutics and previously served on the Board at Avanir Pharmaceuticals, the Generic Pharmaceutical Association, and the California Healthcare Institute.
“I have long admired Apellis’s commitment to advancing innovative therapies for patients with significant unmet needs,” said Mr. Wheeler. “Having previously led an immunology company, I believe that Apellis’s portfolio and scientific approach are among the best in the industry. I look forward to joining the outstanding leadership team at Apellis.”
Mr. Wheeler holds a Master of Business Administration in Finance and Marketing from the Wharton School of the University of Pennsylvania and a Bachelor of Science and Master of Science in Chemical Engineering from Cornell University.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on X and LinkedIn.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Lissa Pavluk
media@apellis.com
617.977.6764
Investor Contact:
Neil Carnahan
neil.carnahan@apellis.com
617.977.5703
FAQ
What experience does Craig Wheeler bring to Apellis Pharmaceuticals' Board?
When did Craig Wheeler join Apellis Pharmaceuticals' Board of Directors?
What was Craig Wheeler's role at Momenta Pharmaceuticals?
What other board positions does Craig Wheeler currently hold?
